As AAPLOG members are aware, we’ve been actively fighting the widespread invasion of abortion pills on women, girls, and preborn children. We led two letters from medical groups, one in July 2025 and another in January 2026, demanding an immediate safety review of mifepristone and the reinstatement of the in-person dispensing requirement.
On Jan. 27, the Department of Justice (DOJ) asked a federal judge to delay or dismiss a Louisiana lawsuit seeking to restore in-person office visits for abortion drugs, citing a Food and Drug Administration (FDA) safety review that could take a year or more to complete.
We certainly hope that this safety review is conducted thoroughly and with appropriate urgency, given the toll these drugs are having on our patients. However, by allowing the Biden-era lack of restrictions around mifepristone to stay in place, the Trump administration enables the FDA to keep the door open for sexual predators to evade responsibility and cause irreversible harm to women, completely substandard care to be given to women in vulnerable situations and for hundreds of thousands of preborn children to lose their lives even in pro-life states.
In their brief, the DOJ essentially claims that neither states nor women harmed by these drugs have the right to sue the FDA. We believe that the FDA is not above the law – especially for women like abortion-pill survivor and plaintiff Rosalie Markezich, whose boyfriend forced her to take the pills.
We’re disappointed that the FDA thinks that it is above the law and can continue to allow women and children to be targeted by abusers and the abortion industry due to a lack of medical oversight of drug-induced abortions. While the administration fails to prioritize patient safety, we’ll continue to stand with women and girls impacted by abortion pills and their abuse, and we will continue to work to hold the FDA accountable to do its job to protect the American people from harmful drugs and to prioritize sound medical practice over any political or ideological priorities.
We want to keep you—our members—fully informed not only of our deep concern, but also of our next steps. This month at MBEC, the nation’s leading pro‑life medical conference, we will be gathering both quantitative and qualitative input from our membership. We will use this information to inform our engagement with White House leadership as we continue advocating for policies that prioritize the safety and care of women, girls, and preborn children.
